JP7448219B2 - Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物 - Google Patents

Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物 Download PDF

Info

Publication number
JP7448219B2
JP7448219B2 JP2020520057A JP2020520057A JP7448219B2 JP 7448219 B2 JP7448219 B2 JP 7448219B2 JP 2020520057 A JP2020520057 A JP 2020520057A JP 2020520057 A JP2020520057 A JP 2020520057A JP 7448219 B2 JP7448219 B2 JP 7448219B2
Authority
JP
Japan
Prior art keywords
amino acid
adam10
seq
regulatory peptide
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020520057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500321A (ja
Inventor
エル モス マルシア
ラスムッセン ロバート
プリンス クリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VERRA THERAPEUTICS
Original Assignee
VERRA THERAPEUTICS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VERRA THERAPEUTICS filed Critical VERRA THERAPEUTICS
Publication of JP2021500321A publication Critical patent/JP2021500321A/ja
Priority to JP2023187803A priority Critical patent/JP2024012470A/ja
Application granted granted Critical
Publication of JP7448219B2 publication Critical patent/JP7448219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24081—ADAM10 endopeptidase (3.4.24.81)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2020520057A 2017-10-02 2018-10-02 Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物 Active JP7448219B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023187803A JP2024012470A (ja) 2017-10-02 2023-11-01 Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762566580P 2017-10-02 2017-10-02
US62/566,580 2017-10-02
US201762589842P 2017-11-22 2017-11-22
US62/589,842 2017-11-22
PCT/US2018/053938 WO2019070685A1 (en) 2017-10-02 2018-10-02 METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023187803A Division JP2024012470A (ja) 2017-10-02 2023-11-01 Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2021500321A JP2021500321A (ja) 2021-01-07
JP7448219B2 true JP7448219B2 (ja) 2024-03-12

Family

ID=65995419

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520057A Active JP7448219B2 (ja) 2017-10-02 2018-10-02 Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物
JP2023187803A Pending JP2024012470A (ja) 2017-10-02 2023-11-01 Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023187803A Pending JP2024012470A (ja) 2017-10-02 2023-11-01 Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物

Country Status (8)

Country Link
US (3) US20190345473A1 (https=)
EP (1) EP3691671A4 (https=)
JP (2) JP7448219B2 (https=)
AU (1) AU2018345601B2 (https=)
CA (1) CA3077694A1 (https=)
IL (1) IL273725A (https=)
MX (1) MX2020004218A (https=)
WO (1) WO2019070685A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3094136A1 (en) 2018-01-31 2019-08-08 Verra Therapeutics LLC Methods and compositions for inhibiting adam9 biological activities
WO2020227714A1 (en) * 2019-05-09 2020-11-12 Verra Therapeutics, Llc Methods and compositions for inhibiting adam8 biological activities
JP2025507975A (ja) * 2022-03-08 2025-03-21 ノバ サウスイースタン ユニバーシティー ディスインテグリンおよびメタロプロテアーゼ１０（ａｄａｍ１０）の酵素・基質選択的エキソサイト阻害剤を用いた関節リウマチ（ｒａ）の処置方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064865A1 (en) 2010-11-09 2012-05-18 The University Of Chicago Role of adam10 and its relevance to disease and therapeutics
US20130059788A1 (en) 2006-08-28 2013-03-07 Duke University Prodomain modulators of adam 10

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024089A2 (en) 2002-09-11 2004-03-25 Sloan-Kettering Institute For Cancer Research Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
AU2004240630B2 (en) * 2003-05-15 2010-10-07 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
AU2006210589B2 (en) 2005-02-02 2011-12-08 Macrogenics West, Inc. ADAM-9 modulators
EP1896580A2 (en) 2005-04-07 2008-03-12 Novartis Vaccines and Diagnostics, Inc. Adam10 in cancer diagnosis, detection and treatment
US20090285840A1 (en) 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
US8079782B1 (en) 2008-05-16 2011-12-20 Hilfiker William K Semi-extensible steel soil reinforcements for mechanically stabilized embankments
WO2012088105A2 (en) * 2010-12-20 2012-06-28 Biozyme Inc. Methods and compositions for predicting disease status in cancer
AU2015213481A1 (en) 2014-02-04 2016-08-25 Ludwig Institute For Cancer Research Ltd Anti-Metalloprotease antibody for diagnosis and treatment of cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130059788A1 (en) 2006-08-28 2013-03-07 Duke University Prodomain modulators of adam 10
WO2012064865A1 (en) 2010-11-09 2012-05-18 The University Of Chicago Role of adam10 and its relevance to disease and therapeutics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Furin is an endogenous regulator of α-secretase associated APP processing，Biochemical and Biophysical Research Communications，2006年，Vol. 349，p. 654-659
The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10，Cellular and Molecular Life Sciences，2013年，Vol. 70，p. 309-333

Also Published As

Publication number Publication date
JP2021500321A (ja) 2021-01-07
JP2024012470A (ja) 2024-01-30
US20230203468A1 (en) 2023-06-29
CA3077694A1 (en) 2019-04-11
MX2020004218A (es) 2020-11-11
AU2018345601B2 (en) 2025-05-15
EP3691671A4 (en) 2022-01-19
AU2018345601A1 (en) 2020-05-21
EP3691671A1 (en) 2020-08-12
US12297469B2 (en) 2025-05-13
WO2019070685A1 (en) 2019-04-11
US20190345473A1 (en) 2019-11-14
US20250207119A1 (en) 2025-06-26
IL273725A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
JP2024012470A (ja) Ａｄａｍ１０の生物学的活性を阻害するための方法および組成物
ES2344734T3 (es) Activacion de miostatina por metaloproteasa, y metodos para modular la actividad de miostatina.
CN110944677B (zh) 局部组合物及用途
US8710014B2 (en) Compositions and methods for inhibition of MMP13:MMP-substrate interactions
Wei et al. Characterization of cathepsin B gene from orange-spotted grouper, Epinephelus coioides involved in SGIV infection
US20250188434A1 (en) Methods and compositions for inhibiting adam9 biological activities
BR122016021558A2 (pt) Polipeptídeos isolados, seus usos, e composição farmacêutica
ES2372388T3 (es) Complejos de factores de crecimiento y modulación de migración y crecimiento celular.
ES2837003T3 (es) Péptidos derivados de BMP-7 para su uso en el tratamiento de la artrosis
JP7641025B2 (ja) 神経損傷及び関連障害を治療するための方法
JP2022531937A (ja) 筋萎縮性側索硬化症を治療するための方法と薬剤
US10813980B2 (en) Methods for treating osteoarthritis by administering linked variants of growth hormone and somatostatin
US9567369B2 (en) Method of treating metastatic cancer
JP2021525251A (ja) 骨癌誘発性アロディニアの抑制
Malferrari et al. Molecular characterization of a novel endonuclease (Xib) and possible involvement in lysosomal glycogen storage disorders
US11541101B1 (en) LEMD3 antagonizes TGF-beta-driven Smad2/3 transcription in a stiffness-dependent fashion in both the nucleus and cytosol
Acton Metalloendopeptidases—Advances in Research and Application: 2012 Edition
US20220213169A1 (en) Methods and compositions for inhibiting adam8 biological activities
HK40099477A (zh) 局部组合物及用途

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200420

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230320

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240221

R150 Certificate of patent or registration of utility model

Ref document number: 7448219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02